XML 24 R8.htm IDEA: XBRL DOCUMENT
v3.20.2

Product Sales | 9 Months Ended
--- | ---
Sep. 30, 2020
Revenues [Abstract] |
Product Sales | Product Sales Net product sales consist of the following:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
Net Product Sales in the United States |  | 2020 |  | 2019 |  | 2020 |  | 2019
EYLEA® |  | $ | 1,318.3 |  |  | $ | 1,187.7 |  |  | $ | 3,604.0 |  |  | $ | 3,422.1 |
Libtayo® |  | 71.6 |  |  | 47.6 |  |  | 196.6 |  |  | 115.2 |
Praluent® |  | 48.5 |  |  | * |  | 95.7 | * |  | *
REGN-COV2 |  | 40.2 |  |  | — |  |  | 40.2 |  |  | — |
ARCALYST® |  | 3.6 |  |  | 3.0 |  |  | 9.3 |  |  | 10.7 |
|  | $ | 1,482.2 |  |  | $ | 1,238.3 |  |  | $ | 3,945.8 |  |  | $ | 3,548.0 |
* Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.
The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September 30, 2020 and 2019. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2020 |  | 2019 |  | 2020 |  | 2019
Besse Medical, a subsidiary of AmerisourceBergen Corporation |  | 50 | % |  | 57 | % |  | 52 | % |  | 57 | %
McKesson Corporation |  | 34 | % |  | 34 | % |  | 34 | % |  | 33 | %

X
- Definition Product Sales and Concentration Risk Disclosure [Text Block] + References No definition available. + Details
Name: | regn_ProductSalesandConcentrationRiskTextBlock
Namespace Prefix: | regn_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration